: DNA-PK inhibitor, NU7441, alleviated mitoxantrone resistance in pediatric primary AML samples. Six pediatric primary AML samples were cultured off or on stroma for 1 hour and treated with 100 nM mitoxantrone and 1 μM NU7441 or DMSO for 24 hours before the analysis of cPARP in all AML cells by FACS. The percent of spontaneous apoptosis (without chemotherapy) was subtracted from the drug-treated samples to yield the percent of apoptosis attributed to drug treatment. The mitoxantrone-induced apoptosis (%cPARP+) was normalized to the apoptosis rate for the Alone / Mito condition, yielding fold change difference. Bars show Mean ± SE. * , p<0.05; ** , p<0.01. AML samples were cultured off or on stroma, treated with 100 nM mitoxantrone for 24 hours, and apoptosis was quantified by FACS analysis for cPARP (A1-A2, B1-B2). The percentage of spontaneous apoptosis was subtracted from the drug-treated samples to yield the percentage of apoptosis attributed to drug treatment (↑cPARP). Cut point analyses separated the cohort into approximate quartiles. The patients were further divided into two populations based on FLT3/ITD status. For the population with FLT3/ITD mutations, 3-year EFS was not different between patients with different mitoxantrone-induced apoptosis rates on HS5 (A1, n=3 and 6 for the lower and higher group, separately) or HS27A stroma (A2, n=2 and 7 for the lower and higher group, separately). For the population without FLT3/ITD mutations, patients whose AML cells had >3.75% mitoxantrone-induced apoptosis on HS5 stroma had higher 3-year EFS, and those with <3.75% mitoxantrone-induced apoptosis on HS5 stroma had lower 3-year EFS (B1, n=4 and 17 for the lower and higher group, separately). Similarly, patients whose AML cells had >3.43% mitoxantrone-induced apoptosis on HS27A stroma had higher 3-year EFS, and those with <3.43% mitoxantrone-induced apoptosis on HS27A stroma had lower 3-year EFS (B2, n=4 and 18 for the lower and higher group, separately). Patient samples were also cultured on or off HS5 stroma for 24 hours, and pY-STAT3 was measured by FACS (A3, B3). Stroma-induced pY-STAT3 is defined as the fold change in MFI over cells cultured alone (ΔMFI). Cut point analysis separated the cohort in half. Again, the patients were further divided into two populations based on FLT3/ITD status. For the population with FLT3/ITD mutations, 3-year EFS was not different among patients with different HS5-induced pY-STAT3 (A3, n=5 and 6 for the lower and higher group, separately). For the population without FLT3/ITD mutations (B3, n=13 and 12 for the lower and higher group, separately), the patients whose AML cells failed to induce pY-STAT3 (stroma-induced pY-STAT3 < 1.22) when co-cultured with HS5 cells had significantly lower 3-year EFS than those whose AML cells appropriately induced pY-STAT3 (> 1.22 
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